Lanzul

Lansoprazole, the active ingredient in Lanzul, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is employed in the management of acid‑related disorders such as gastro‑esophageal reflux disease, erosive esophagitis, peptic ulcer disease, and in combination regimens for Helicobacter pylori eradication.

GNH USA supplies Lanzul as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable product availability across global markets.

Lansoprazole is indicated for several acid‑related gastrointestinal conditions, acting to suppress gastric acid secretion.

Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing acid exposure in the esophagus. Erosive esophagitis: promotes healing of inflamed esophageal tissue by maintaining a higher gastric pH. Peptic ulcer disease: facilitates ulcer closure and symptom relief through sustained acid suppression. Helicobacter pylori eradication: used as part of triple‑therapy regimens to enhance antibiotic effectiveness by creating a less acidic environment.

Lansoprazole may cause adverse reactions ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools that may resolve with continued therapy. - Abdominal pain: discomfort or cramping in the stomach region. - Nausea: feeling of sickness or urge to vomit. - Constipation: difficulty passing stools. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reactions: anaphylaxis, Stevens‑Johnson syndrome, or toxic epidermal necrolysis. - Low serum magnesium: hypomagnesemia leading to muscle cramps, arrhythmias, or seizures. - Bone fractures: increased risk of hip, wrist, or vertebral fractures with long‑term use. - Interstitial nephritis: kidney inflammation causing reduced renal function. - Hepatotoxicity: elevated liver enzymes or hepatitis.

Before initiating lansoprazole therapy, consider the following precautions to ensure safe use. - Renal or hepatic impairment: assess function and adjust therapy if needed. - Long‑term use: evaluate necessity periodically to avoid potential risks such as fractures or nutrient deficiencies. - Concomitant medications: review for drugs that may interact or require dose adjustments. - Pregnancy and lactation: use only if benefits outweigh potential risks; discuss with healthcare provider. - Elderly patients: monitor for increased susceptibility to adverse effects. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Lansoprazole can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events. - Atazanavir or other HIV protease inhibitors: markedly decreased absorption, loss of antiviral efficacy. - Methotrexate (high dose): increased toxicity due to reduced renal clearance. - Warfarin: potential alteration of INR, requiring close monitoring. - Digoxin: increased serum levels, risk of toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: decreased plasma concentration, may reduce seizure control. - Carbamazepine: enhanced metabolism leading to lower levels. - Ketoconazole or other azole antifungals: increased exposure, risk of toxicity. - Fluconazole: may increase lansoprazole levels, monitor for side effects. - Vitamin B12 supplements: reduced absorption, consider monitoring levels.